Join Complimentary Webinar: SCOTUS Update: Impact of Halo and Stryker on Enhanced Patent Damages Assessments, Thu, Feb 4, 2016 1:00 PM – 2:00 PM EST

In October, the Supreme Court consolidated and granted cert in two enhanced fee award patent cases: Halo Electronics, Inc. v. Pulse Electronics, Inc., S.Ct. No. 14-1513 and Stryker Corp. v. Zimmer, Inc., No. 14-1520. The Court will focus on the whether the Federal Circuit’s stringent test limited damages is appropriate. This 60 minute webinar will…

Available Now – Slides from the 2015 Paragraph IV Disputes Forum

It is our pleasure to share these slides from the April 2015 conference with you. They cover key and evolving topics that we will continue to explore in 2016: http://hatch-waxmanevents.com/resources.html 

Check out all of the highlights from ACI's 9th Annual Paragraph IV Disputes

Check out all of the highlights from ACI’s 9th Annual Paragraph IV Disputes Click here to learn more about American Conference Institute’s (ACI’s) 10th Annual Paragraph IV Disputes conference, April 25 & 26, 2016 in NYC.

Best Rates for PIV Chicago Expire in 5 Days

Yes — you heard it right. In 5 business days, best rates to attend ACI’s Paragraph IV Master Symposium will expire. You surely don’t want to miss out on early bird pricing to attend our ACI’s industry-leading advanced forum for brand name and generic counsel on the intricacies of extreme Hatch-Waxman litigation.  Join us on…

5 Top Reasons to Attend ACI’s Paragraph IV Disputes Master Symposium in Chicago

Here are 5 reasons why you must attend ACI’s Paragraph IV Master Symposium in Chicago this fall: 1. It’s Where All the Key Industry Players Will Be! Leading in-house and law firm pharmaceutical patent attorneys — for brand names and generics as well as the biopharmaceutical industry – will gather at this event — in the…

After a slow start, generic pharmaceutical companies now accelerate their use of inter partes review patent challenges

Expert article by Joseph E. Cwik on April 29, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. When inter partes review actions first became available in 2012, no generic pharma companies availed themselves to this litigation tool. Not until 2013 did a generic pharma company first seek inter…

The business case for inter partes review of patents by generic pharma

Expert article by Joseph E. Cwik on May 27, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. Several parts of the America Invents Act (the “AIA”) became law on Sept. 16, 2012, sparking some of the most meaningful changes to patent law seen in decades. One hot provision…

Husch Blackwell leads the charge in first inter partes review wins against pharmaceutical-related patents

Expert article by Joseph E. Cwik and Josh Nosal on July 2, 2014. Originally published on Healthcare Law Insights, reposted with the permission of Joseph E. Cwik. The Patent Trial and Appeal Board (PTAB) issued its first final written decisions June 20, 2014, in four inter partes reviews (IPR) of pharmaceutical-related patents. The four decisions…

June Conference Materials are Now Available!

 June was a productive month for ACI’s conference attendees. At our events, decision makers had the chance to acquire top notch industry information; ranging from the latest trends, developments, hottest litigation cases to key insights from leading experts and more. You now have the opportunity to remain ahead of the curve too by accessing conference materials.…

Paragraph IV Disputes Ebook: Best Practice Tips from Speakers

 ACI’s 8th Annual Paragraph IV Dispute  took place earlier this year in New York.  We asked speakers to share their best practices for a complimentary e-book.Don’t miss out on  valuable insights  from Christopher R. Noyes,  David A. Manspeizer, Paul A. Ragusa, and Stephen R. Auten.                 Upcoming Event        When: September…